Stanislav M. Ivanov

Stanislav M. Ivanov

Auto-generated profile, based on publicly available information

Stanislav M. Ivanov

N.N. Blokhin National Medical Research Center of Oncology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
IGI. A. Gladilina
I. A. Gladilina
MSM. A. Shabanov
M. A. Shabanov
OKO. A. Kravets
O. A. Kravets
FZF. O. Zakhidova
F. O. Zakhidova
SIS. M. Ivanov
S. M. Ivanov
SCSvetlana Chulkova
Svetlana Chulkova
Постлучевые повреждения легких

23 April 2024 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
YBYu.A. Barsukov
Yu.A. Barsukov
ZMZ.Z. Mamedli
Z.Z. Mamedli
STS.I. Tkachev
S.I. Tkachev
VAV.A. Aliev
V.A. Aliev
OVO.A. Vlasov
O.A. Vlasov
SIS.M. Ivanov
S.M. Ivanov
OBJECTIVE To improve the results of treatment of patients with locally advanced rectal cancer by creating a new variant of neoadjuvant therapy using polyradiomodification and systemic polychemotherapy. MATERIAL AND METHODS 46 patients with locally advanced rectal cancer of stage T(3cd-4a)N(1c-2)M0, CRM+, EMVI+ were included in the program. RT was performed in hypofractionation mode from 4 G to SOD 40 G 3 times a week against the background of systemic polychemotherapy with Capecitabine 850 mg/m2 per os 2 times a day for 1—22 days and Oxaliplatin 50 mg/m2 iv on the 3rd, 10th and 17th days. Polyradiomodification was carried out by conducting 5 sessions of local microwave hyperthermia for 60 minutes at a temperature of 43—45 °C on the 8th, 10th, 15th, 17th and 22nd days and rectal administration of a biopolymer composition with Metronidazole at a dose of 10 g/m2 on the 8th and 15thth days. The control group included 88 patients with neoadjuvant remote RT in a single focal dose 2Gy to to a total focal dose of 52—56 Gy while taking Capecitabine at 825 mg/m2 twice a day during the course of treatment. The operations were performed 6—8 weeks after completion of the course of CRT and a control clinical examination. RESULTS When using the new treatment option, there was an increase in registered toxicity by 1.5 times and toxicity of 3—4 degrees by 2.5 times, however, in all patients the planned course of treatment was completed. Therapeutic pathomorphosis of the III and IV degrees was achieved in 76.4% compared with 30.6% in the control group (p=0.0001). The incidence of cancer recurrence was reduced from 12.5% to 2.2% (p=0.0469), and distant metastases — from 31.8% to 8.7% (p=0.0008). The five-year disease-free survival rate was increased from 56.8% to 81.0% (p=0.02031). CONCLUSION The results of the application of the created treatment option for patients with locally advanced rectal cancer indicate the prospects of combining polyradiomodification with systemic polychemotherapy.

31 December 2020 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
TBT. N. Borisova
T. N. Borisova
STS. I. Tkachev
S. I. Tkachev
SIS. M. Ivanov
S. M. Ivanov
SAS. B. Alieva
S. B. Alieva
OTO. P. Trofimova
O. P. Trofimova
DMD. T. Marinov
D. T. Marinov
Лучевая терапия в комплексном лечении больных мезотелиомой плевры

22 June 2021 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
LGL. A. Gladilina
L. A. Gladilina
MSM. A. Shabanov
M. A. Shabanov
FZF. O. Zakhidova
F. O. Zakhidova
ATAlexey Tryakin
Alexey Tryakin
OMO. A. Malikhova
O. A. Malikhova
LVL. A. Vashakmadze
L. A. Vashakmadze
Background: The incidence of esophageal cancer is increasing. In this connection, the search for the most effective methods of treating this disease continues. In most patients, esophageal cancer is diagnosed at III– IV stages of the disease. Currently, the standard of treatment for inoperable patients is chemo radiotherapy. Brachytherapy is one of the perspective methods of radiation therapy. Using of brachytherapy in the complex treatment of patients with esophageal cancer makes possible to increase the radiation dose without increasing the risk of complications after treatment.Methods: The study included 20 patients with inoperable esophageal cancer (most of them with III stages, 60 %). The age of the patients is from 51 to 89 years, ECOG performance status ½ (25 %/75 %), dysphagia score 1/2/3–4 (25 %,50 %, 25 %). All patients were diagnosed with esophageal squamous cell carcinoma. Most patients were with tumor in the middle third of the esophagus (70 %). The greatest length of the tumor was 10 cm. On the first stage of treatment patients underwent external-beam radiation therapy 46 Gy in 2 Gy fractions with simultaneous chemotherapy. After that, brachytherapy was performed (single dose of 5 Gy, 2 fractions with an interval of 6–7 days, 62,8 Gy (EQD2, α/β = 10 Gy).Results: Patients received therapy support for cardiovascular and lung diseases and nutritional support before, during and following chemoradiotherapy. There were no patients with hematological toxicity grade 3–4. Esophagitis grade 2 was noted in 40 % of patients, grade 1 in 60 % of patients. Esophagitis resolved on its own 2 weeks after completion of therapy. Complete tumor regression was observed in 10 % of patients, partial regression in 80 % of patients, stabilization of tumor process was observed in 10 % of patients. All patients have a poor QOL due to physical and psychological disorders. The general health situation and physical function after 3 months of treatment was improved compared to the prior to treatment period.

21 December 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
TBT. N. Borisova
T. N. Borisova
ANA. V. Nazarenko
A. V. Nazarenko
KLK. K. Laktionov
K. K. Laktionov
STS. I. Tkachev
S. I. Tkachev
SAS. B. Alieva
S. B. Alieva
SGS. G. Gerasimov
S. G. Gerasimov
Introduction. Nowadays the stereotactic radiotherapy (SRT) of patients with clinical stage I-II lung cancer is the choice of the treatment modality for functionally inoperable patients. It shows safety and high efficiency in reaching the local control. Though there is a range of unsolved issues connected with the prediction of treatment efficiency and frequency of complications, an integration of new technologies in the planning and treatment process allows to widen the search of the predictive factors.Materials and methods. Since 2014, 42 patients (T1N0M0 – 16 patients, T2N0M0 – 26 patients) with clinical stage I-IIa lung cancer have underwent SRT. The majority of patients (38) have been recognized as functionally inoperable due to the concurrent broncho-pulmonary pathology, 4 conditionally operable patients have refused an operation. 11 patients had the primary multiple tumors in their anamneses, 3 patients had a сentral tumor. Used dose fractionation options were: 10 Gy х 5 fractions (n = 29) and 7 Gy х 8 fractions (n = 13) – BED = 100 Gy.Resuts. The median follow-up was 32 months (range 6–56 months). The 3-year local control was 94%. The isolated local recurrences were not registered. Overall 3-year survival rate was 74% (95% CI, 60–90) and a 3-year tumor-specific survival rate – 84% (95% CI, 71–98). During one-factor analysis a reliable influence on the prognosis of the fractionation regimen (р = 0,04) and, close to reliability, the initial SUVmax level influence (р = 0,07) were revealed. Grade 3 pulmonary toxicity was observed in 4 (9%) patients, one patient with a Central tumor died from pulmonary hemorrhage (grade 5 toxicity). Grade 3 chest pain was observed in 3 (7%) patients, two of them had a rib fracture.Conclusions. With modern approaches to SRT treatment planning and delivery there should be a search for additional treatment efficiency and toxicity predictors. The total dose delivery regimen and initial tumor SUVmax can be predictive efficiency factors, while the pulmonary tissue volume can be a predictive toxicity factor.

31 December 2020 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
TBTatiana N. Borisova
Tatiana N. Borisova
STSergey I. Tkachev
Sergey I. Tkachev
SIStanislav M. Ivanov
Stanislav M. Ivanov
SASevil B. Alieva
Sevil B. Alieva
OTOxana P. Trofimova
Oxana P. Trofimova
AAAmir G. Abdullaev
Amir G. Abdullaev
Pleural mesothelioma (PM) remains a disease with a poor prognosis, despite the use of the newest achievements of multimodal treatment. Radiation therapy for PM is traditionally used in some directions: in radical treatment as a part of a three-modal approach, for reducing the risk of chest metastasis in areas of invasive interventions and during palliative treatment. The lack of reliable randomized trials has led to an absence of consensus about the optimal radical treatment strategy. Mordern global recommendations for the treatment of PM are controversial regarding the use of adjuvant radiotherapy in multimodal treatment. Although the role of radiation therapy in the treatment of PM remains unclear, significant successes in planning and conducting radiotherapy are showing that long-term survival can be achieved for these patients, for whom, until recently, only palliative treatment was considered as appropriate treatment. For many years, preventive irradiation of areas of invasive interventions has been used as a method to prevent implantation metastasis. However, a number of randomized trials and recent meta-analysis have not demonstrated the benefits of this treatment approach. Due to the rarity of PM, the severe state of patients and tumor localization, the importance of radiation therapy in the palliative treatment of patients with pleural mesothelioma remains controversial. Recent completed and planned studies allow to commend the role of palliative radiation and recommend it in order to reduce pain.